Werewolf Therapeutics (HOWL) Stock Price, News & Analysis

Company Overview

Werewolf Therapeutics, Inc. (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs. These investigational agents are engineered to engage key immune pathways—such as T-cell activation and pro-inflammatory cytokine signaling—only when proteolytically processed by enzymes present in the tumor milieu. This approach is intended to drive a potent, localized immune response against cancer cells while reducing the risk of adverse events associated with systemic cytokine exposure.

The company’s pipeline spans both preclinical and early clinical stages, with lead programs targeting interleukin and tumor-necrosis factor family members. In addition to internal research efforts, Werewolf Therapeutics collaborates with academic institutions and industry partners to explore combination regimens that may further enhance the anti-tumor activity of its conditional agents.

Founded in 2019 and headquartered in Cambridge, Massachusetts, Werewolf Therapeutics is led by a management team with extensive experience in immuno-oncology drug discovery and clinical development. The company is focused on advancing its pipeline through regulatory milestones and clinical proof-of-concept studies in the United States.

Key Stats

• Today's Range: $0.38 to $0.41
• 50-Day Range: $0.31 to $0.50
• 52-Week Range: $0.27 to $2.38
• Volume: 156,511 shs
• Average Volume: 740,438 shs
• Market Capitalization: $18.57 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.75
• Consensus Rating: Hold

Werewolf Therapeutics Stock Analysis - MarketRank™

Werewolf Therapeutics scored higher than 52% of companies evaluated by MarketBeat, and ranked 586th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Hold

Consensus Rating

Werewolf Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on no strong buy ratings, 2 buy ratings, 4 hold ratings, and 1 sell rating.

Upside Potential

Werewolf Therapeutics has a consensus price target of $3.75, representing about 881.7% upside from its current price of $0.38.

Amount of Analyst Coverage

Werewolf Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Werewolf Therapeutics are expected to grow in the coming year, from ($1.08) to ($0.99) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Werewolf Therapeutics is -0.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Werewolf Therapeutics is -0.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Werewolf Therapeutics has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.52% of the float of Werewolf Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Werewolf Therapeutics has a short interest ratio ("days to cover") of 1.03, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Werewolf Therapeutics has recently increased by 10.30%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Werewolf Therapeutics does not currently pay a dividend.

Dividend Growth

Werewolf Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Werewolf Therapeutics this week, compared to 5 articles on an average week.

Search Interest

Only 1 people have searched for HOWL on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

MarketBeat Follows

3 people have added Werewolf Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Werewolf Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,171,786.00 in company stock.

Percentage Held by Insiders

23.60% of the stock of Werewolf Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

64.84% of the stock of Werewolf Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/31/2026
• Today: 8/10/2026
• Next Earnings (Estimated): 8/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:HOWL
• CIK: 1785530
• Web: werewolftx.com
• Phone: 617-952-0555
• Fax: N/A
• Employees: 40
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Werewolf Therapeutics: $3.75
• High Price Target: $7.00
• Low Price Target: $1.00
• Potential Upside/Downside: +881.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.14
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.76)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$60.82 million
• Net Margins: N/A
• Pretax Margin: -164.82%
• Return on Equity: -166.99%
• Return on Assets: -59.88%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.91
• Quick Ratio: 2.91

Sales & Book Value

• Annual Sales: $1.88 million
• Price / Sales: 9.88
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.51 per share
• Price / Book: 0.75

Miscellaneous

• Outstanding Shares: 48,600,000
• Free Float: 37,130,000
• Market Cap: $18.57 million
• Optionable: Optionable
• Beta: 0.29